Cited by 164Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsProtein purification and stability

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Fully human therapeutic monoclonal antibodies.

Weiner, Louis M·2006·Journal of Immunotherapy

DOI 10.1097/01.cji.0000192105.24583.83

Open this paper in CoChat — free account

Abstract

Monoclonal antibody (mAb) therapy has been facilitated by a number of technologic advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of mAbs; thus, immunogenicity remained a concern. Further elimination of rodent sequences enabled the production of humanized mAbs, followed by current technology using phage display and, finally, transgenic mice technology, which allows for the generation of fully human therapeutic mAbs. The reduced immunogenicity of this new generation of mAbs is expected to enhance efficacy, safety, and ease of use. In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues.

Integrity signals

Registry

Crossref · 10.1097/01.cji.0000192105.24583.83

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
By-passing immunization
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. P. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,605
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function
McCune, J. M., Namikawa, R., Kaneshima, H., Shultz, L. D., Lieberman, M., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2971269 · Cited by 1,404

Show all 36 references

Research works printed but not linked: 5

Skamene, 1971, Clin Exp Immunol, 8, 195
Hale, 1983, Mol Biol Med, 1, 321
Yokota, 1993, Cancer Res, 53, 3776
Adams, 2001, Cancer Res, 61, 4750
Milenic, 1991, Cancer Res, 51, 6363

Sorted by citations

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,362
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Recent advances in large-scale production of monoclonal antibodies and related proteins
Shukla, A. A., & Thömmes, J. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 601
Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Polymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of drug targeting · doi:10.1080/10611860701794353 · Cited by 427
The pharmacology and therapeutic applications of monoclonal antibodies
Castelli, S., McGonigle, P., & Hornby, P. J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.535 · Cited by 407
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G. R., Tam, S. H., Sague, S. L., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 246
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Bioanalytical LC–MS/MS of protein-based biopharmaceuticals
van den Broek, I., Niessen, W. M. A., & van Dongen, W. D. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.04.030 · Cited by 238
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 236
Nanomedicine
Parveen, S., & Sahoo, S. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00002 · Cited by 192
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
Therapeutic monoclonal antibodies in ophthalmology
Rodrigues, E. B., Farah, M. E., Maia, M., Penha, F. M., Regatieri, C. V., Melo, G. B., Pinheiro, M. M., & Zanetti, C. R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.005 · Cited by 177
In vivoapplications of magnetic nanoparticle hyperthermia
Hilger, I. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.832815 · Cited by 175
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
Cutsem, E. V., Siena, S., Humblet, Y., Canon, J.-L., Maurel, J., Bajetta, E., Neyns, B., Kotasek, D., Santoro, A., Scheithauer, W., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm399 · Cited by 155
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Clinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 138
Improving the Oral Efficacy of Recombinant Granulocyte Colony-Stimulating Factor and Transferrin Fusion Protein by Spacer Optimization
Bai, Y., & Shen, W. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9059-5 · Cited by 135
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 131
Engineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 132
The biology of Ku and its potential oncogenic role in cancer
Gullo, C. A., Au, M., Ge, F., & Teoh, G. K. H. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.01.001 · Cited by 128
Antibody engineering and modification technologies
Filpula, D. R. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.03.004 · Cited by 131
Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
Schirrmann, T., Meyer, T., Schütte, M., Frenzel, A., & Hust, M. (2011) · Molecules · doi:10.3390/molecules16010412 · Cited by 129
Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
Li, S., Kussie, P. H., & Ferguson, K. M. (2008) · Structure · doi:10.1016/j.str.2007.11.009 · Cited by 120
Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain
Schnitzer, T. J., Lane, N. E., Birbara, C. A., Smith, M. D., Simpson, S. L., & Brown, M. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.01.009 · Cited by 118
Absolute Quantification of Monoclonal Antibodies in Biofluids by Liquid Chromatography−Tandem Mass Spectrometry
Hagman, C., Ricke, D. O., Ewert, S., Bek, S., Falchetto, R. A., & Bitsch, F. (2008) · Analytical Chemistry · doi:10.1021/ac702115b · Cited by 115
Evolution and Emergence of Therapeutic Monoclonal Antibodies
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 109
The role of osteoprotegerin in cardiovascular disease
Montagnana, M., Lippi, G., Danese, E., & Guidi, G. C. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.727019 · Cited by 99
Panitumumab
Keating, G. M. (2010) · Drugs · doi:10.2165/11205090-000000000-00000 · Cited by 94
A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis
de Kruif, J., Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Throsby, M., Rupprecht, C. E., & Goudsmit, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145053 · Cited by 88
A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use
Wagner, K. S., Stickings, P., White, J. M., Neal, S., Crowcroft, N. S., Sesardic, D., & Efstratiou, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.094 · Cited by 76
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 78
Self-citation
Recombinant Antibodies and In Vitro Selection Technologies
Geyer, C. R., McCafferty, J., Dübel, S., Bradbury, A. M., & Sidhu, S. S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-931-0_2 · Cited by 73
Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody
Olafsen, T., Gu, Z., Sherman, M. A., Leyton, J. V., Witkosky, M. E., Shively, J. E., Raubitschek, A. A., Morrison, S. L., Wu, A. M., & Reiter, R. E. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318031b53b · Cited by 70
A Universal Strategy for Development of a Method for Absolute Quantification of Therapeutic Monoclonal Antibodies in Biological Matrices Using Differential Dimethyl Labeling Coupled with Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry
Ji, C., Sadagopan, N., Zhang, Y., & Lepsy, C. S. (2009) · Analytical Chemistry · doi:10.1021/ac901800f · Cited by 67
Mining human antibody repertoires
Beerli, R. R., & Rader, C. M. (2010) · mAbs · doi:10.4161/mabs.12187 · Cited by 57
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 56
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer
Pedretti, M., Soltermann, A., Arni, S., Weder, W., Neri, D., & Hillinger, S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.07.013 · Cited by 55
Mucosal injury from targeted anti-cancer therapy
Keefe, D. M. K., & Gibson, R. J. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0181-z · Cited by 54
The present state of the art in expression, production and characterization of monoclonal antibodies
Gaughan, C. L. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9625-z · Cited by 57
Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies
Pedretti, M., Rančić, Z., Soltermann, A., Herzog, B. A., Schliemann, C., Lachat, M. L., Neri, D., & Kaufmann, P. A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.043 · Cited by 52
Masked Selection: A Straightforward and Flexible Approach for the Selection of Binders Against Specific Epitopes and Differentially Expressed Proteins by Phage Display
Even-Desrumeaux, K., Névoltris, D., Lavaut, M. N., Alim, K., Borg, J., Audebert, S., Kerfélec, B., Baty, D., & Chames, P. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.025486 · Cited by 55
Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody
Apgar, J. R., Mader, M., Agostinelli, R., Benard, S., Bialek, P., Johnson, M., Gao, Y., Krebs, M. R. H., Owens, J. M., Parris, K. D., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1215786 · Cited by 54
Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers
Lazar, H., Horn, M. P., Zuercher, A. W., Imboden, M. A., Durrer, P., Seiberling, M., Pokorny, R., Hammer, C., & Lang, A. B. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01699-08 · Cited by 52
Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study.
Lyer, S., Tietze, R., Jurgons, R., Struffert, T., Engelhorn, T., Schreiber, E., Dörfler, A., & Alexiou, C. (2010) · PubMed · Cited by 49
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 49
Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy
Wu, J., Schultz, J. S., Weldon, C. L., Sule, S. V., Chai, Q., Geng, S. B., Dickinson, C. D., & Tessier, P. M. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv045 · Cited by 48
Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
Lamoureux, F., Picarda, G. G. A., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédiní, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0497 · Cited by 50
Monoclonal antibody purification and its progression to commercial scale
Chahar, D. S., Ravindran, S., & Pisal, S. S. (2019) · Biologicals · doi:10.1016/j.biologicals.2019.09.007 · Cited by 45
Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections
Seixas, A. M. M., Sousa, S. A., & Leitão, J. H. (2022) · Vaccines · doi:10.3390/vaccines10111789 · Cited by 44
Recombinant plasma proteins
Burnouf, T. (2010) · Vox Sanguinis · doi:10.1111/j.1423-0410.2010.01384.x · Cited by 48
An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors
Stephenson, J., Gregory, C., Burris, H. A., Larson, T., Verma, U. N., Cohn, A. L., Crawford, J., Cohen, R. B., Martin, J., Lum, P., et al. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.005 · Cited by 43
Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review
Suh, K., Kyei, I., & Hage, D. S. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200112 · Cited by 43
Research and development of therapeutic mAbs: An analysis based on pipeline projects
Geng, X., Kong, X., Hu, H., Chen, J., Yang, F. Q., Liang, H., Chen, X., & Yuanjia, H. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1074362 · Cited by 41
Bacteriophages in health and disease
Hyman, P., & Abedon, S. T. (2012) · CABI eBooks · doi:10.1079/9781845939847.0000 · Cited by 41
Top-Down Lc–Ms Quantitation of Intact Denatured and Native Monoclonal Antibodies in Biological Samples
Zhang, L., Vasicek, L. A., Hsieh, S., Zhang, S., Bateman, K. P., & Henion, J. D. (2018) · Bioanalysis · doi:10.4155/bio-2017-0282 · Cited by 40
Pros and Cons of the Immunogenicity of Monoclonal Antibodies in Cancer Treatment: A Lesson from Autoimmune Diseases
Talotta, R., Rucci, F., Canti, G. L., & Scaglione, F. (2019) · Immunotherapy · doi:10.2217/imt-2018-0081 · Cited by 40
Current status and perspectives of biopharmaceutical drugs
Ryu, J. K., Kim, H. S., & Nam, D. H. (2012) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-012-0095-1 · Cited by 39
A sensitive amperometric immunosensor for the detection of carcinoembryonic antigen using ZnMn2O4@reduced graphene oxide composites as signal amplifier
Fan, X., Deng, D., Chen, Z., Qi, J., Li, Y., Han, B., Huan, K., & Luo, L. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.129852 · Cited by 36
Panitumumab
Hoy, S. M., & Wagstaff, A. J. (2006) · Drugs · doi:10.2165/00003495-200666150-00011 · Cited by 35
Codon engineering for improved antibody expression in mammalian cells
Carton, J. M., Sauerwald, T. M., Hawley‐Nelson, P., Morse, B. A., Peffer, N. J., Beck, H., Lu, J., Cotty, A., Amegadzie, B. Y., & Sweet, R. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2007.05.017 · Cited by 34
Frontier of therapeutic antibody discovery: The challenges and how to face them
Lu, Z. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i12.187 · Cited by 30
Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review
Azevedo, R., Ferreira, J. A., Peixoto, A., Neves, M., Sousa, N., Lima, Á., & Santos, L. L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.002 · Cited by 30
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
Stamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 30
Membrane‐tethered proteins for basic research, imaging, and therapy
Cheng, T., & Roffler, S. R. (2008) · Medicinal Research Reviews · doi:10.1002/med.20127 · Cited by 28
Use of Generic LC–MS/MS Assays to Characterize Atypical PK Profile of A Biotherapeutic Monoclonal Antibody
Law, W. S., Genin, J., Miess, C., Tréton, G., Warren, A. P., Lloyd, P. M., Dudal, S., & Krantz, C. (2014) · Bioanalysis · doi:10.4155/bio.14.167 · Cited by 26
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Immunogenicity of panitumumab in combination chemotherapy clinical trials
Weeraratne, D. K., Chen, A., Pennucci, J. J., Wu, C., Zhang, K., Wright, J., Ruixo, J. J. P., Yang, B., Kaliyaperumal, A., Gupta, S., et al. (2011) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-11-17 · Cited by 26
In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
Muñoz, R., Arias, Y., Ferreras, J. M., Jiménez, P., Langa, C., Rojo, M. A., Gayoso, M. J., Córdoba-Díaz, D., Bernabéu, C., & Girbés, T. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1357-7 · Cited by 25
Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3
Pfaffen, S., Hemmerle, T., Weber, M., & Neri, D. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.11.004 · Cited by 25
Antibody Phage Display
Hust, M., Thie, H., Schirrmann, T., & Dübel, S. (2009) · doi:10.1002/9780470485408.ch8 · Cited by 25
Stable Supply of Large Amounts of Human Fab from the Inclusion Bodies in E. coli
Fujii, T., Ohkuri, T., Onodera, R., & Ueda, T. (2007) · The Journal of Biochemistry · doi:10.1093/jb/mvm075 · Cited by 24
The role and efficacy of denosumab in the treatment of osteoporosis: an update
Charopoulos, I., Orme, S. M., & Giannoudis, P. V. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.516249 · Cited by 26
Technological advances in mucositis research: New insights and new issues
Gibson, R. J., Bowen, J. M., & Keefe, D. M. K. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.001 · Cited by 23
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor
Rolfo, C. D., Raez, L. E., Russo, A. G., Reguart, N., Campelo, R. G., Bronte, G., Papadimitriou, K., & Silvestris, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.843667 · Cited by 20
Opportunities and Challenges for Antibodies against Intracellular Antigens
Yang, X., Xie, S., Yang, X., Jumbo, J. C. C., Hou, X., Tang, Z., Yao, H., Mo, F., Yin, S., Liu, A., et al. (2019) · Theranostics · doi:10.7150/thno.35486 · Cited by 22
Miniaturized single-cell technologies for monoclonal antibody discovery
Lent, J. V., Breukers, J., Ven, K., Ampofo, L., Horta, S., Pollet, F., Imbrechts, M., Geukens, N., Vanhoorelbeke, K., Declerck, P. J., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00243k · Cited by 22
Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies
Lee, S. C., López‐Albaitero, A., & Ferris, R. L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0023-5 · Cited by 21
Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Frenzel, A., Fröde, D., Meyer, T., Schirrmann, T., & Hust, M. (2011) · Current Biotechnology · doi:10.2174/2211550111201010033 · Cited by 19
Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors
Kast, J., Dutta, S., & Upreti, V. V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01809-4 · Cited by 18
Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study
Cong, Y., Zhang, Z., Zhang, S., Hu, L., & Gu, J. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500098 · Cited by 17
Inhibition of osteoclastogenesis by RNA interference targeting RANK
Ma, R., Xu, J., Dong, B., Kauther, M. D., Jäger, M., & Wedemeyer, C. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-154 · Cited by 15
Downregulation of Peroxiredoxin I by a Novel Fully Human Phage Display Recombinant Antibody Induces Apoptosis and Enhances Radiation Sensitization in A549 Lung Carcinoma Cells
Guo, Q., Huang, X., Zhang, J., Luo, Y., Peng, Z., & Li, S. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.0989 · Cited by 14
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA
Sgier, D., Zuberbuehler, K., Pfaffen, S., & Neri, D. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp089 · Cited by 14
Monoclonal Antibodies: From Structure to Therapeutic Application
Davis, J. D., Deng, R., Boswell, C. A., Zhang, Y., Li, J., Fielder, P. J., Joshi, A., & Kenkare-Mitra, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6486-0_7 · Cited by 14
Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Bahrami, S., Kazemi, B., Zali, H., Black, P. C., Basiri, A., Bandehpour, M., Hedayati, M., & Sahebkar, A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666191016124935 · Cited by 13
Therapeutic Recombinant Monoclonal Antibodies
Bakhtiar, R. (2012) · Journal of Chemical Education · doi:10.1021/ed200392h · Cited by 12
EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Kanwar, S. S., Nautiyal, J., & Majumdar, A. P. N. (2010) · Current Drug Targets · doi:10.2174/138945010791170851 · Cited by 12
Biologic Therapy
Eisenberg, S. (2012) · Journal of Infusion Nursing · doi:10.1097/nan.0b013e31826579aa · Cited by 11
Denosumab for the Management of Postmenopausal Osteoporosis
Singer, A. J., & Grauer, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2235 · Cited by 11
New Trends in Epidermal Growth Factor Receptor-Directed Monoclonal Antibodies
Markman, B., Capdevila, J., Élez, E., & Tabernero, J. M. (2009) · Immunotherapy · doi:10.2217/imt.09.66 · Cited by 10
Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
van de Weert, M., & Møller, E. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-75841-1_5 · Cited by 10
Qualification and application of a liquid chromatography–quadrupole time‐of‐flight mass spectrometric method for the determination of trastuzumab in rat plasma
Park, M., Lee, M., & Shin, Y. G. (2015) · Biomedical Chromatography · doi:10.1002/bmc.3606 · Cited by 9
Cattle-derived knob paratopes grafted onto peripheral loops of the IgG1 Fc region enable the generation of a novel symmetric bispecific antibody format
Yanakieva, D., Vollmer, L., Evers, A., Siegmund, V., Arras, P., Pekar, L., Doerner, A., Valldorf, B., Kolmar, H., Zielonka, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1238313 · Cited by 8
Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen
Dong, L., Masaki, Y., Takegami, T., Kawanami, T., Itoh, K., Jin, Z., Huang, C.-R., Tong, X., Fukushima, T., Tanaka, M., et al. (2007) · International Immunology · doi:10.1093/intimm/dxl150 · Cited by 8
History of monoclonal antibodies and lessons for the development of stem cell therapeutics
Vertès, A. A., & Dowden, N. J. (2015) · Wiley eBooks · doi:10.1002/9781118846193.ch33 · Cited by 8
Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5
Liu, J., Di, G., Wu, C.-T., Hu, X., & Duan, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.089 · Cited by 7
Nanomedicine: Drug Delivery Systems and Nanoparticle Targeting
윤혜원, 강건욱, 정준기, & 이동수 (2008) · Nuclear Medicine and Molecular Imaging · Cited by 7
Genetic Engineering Antibody: Principles and Application
Zhao, L., Wu, Q., Song, R., & Yun, Z. (2019) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/612/2/022045 · Cited by 7

Authors: Weiner, L. M.
Affiliations: Fox Chase Cancer Center (US)
Corresponding author: Weiner, Louis M
ORCID: Weiner, Louis M
Venue: Journal of Immunotherapy
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2006-01
Volume: 29
Issue: 1
Pages: 1-9
ISSN: 1524-9557 (ISSN-L)
DOI: 10.1097/01.cji.0000192105.24583.83
OpenAlex: W1971456299
Cited by: 164
References: 36
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 17
FWCI: 2.09
Type: journal article
Language: en
Open access: closed
Locations: Journal of Immunotherapy (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 50633, CA06926, R01CA050633)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords: monoclonal antibodies, fully human antibodies, immunogenicity, chimeric antibodies, humanized monoclonal antibody, transgenic mice, phage display, hybridoma technology, antibody engineering, therapeutic antibodies
MeSH terms: Animals, Antibodies, Monoclonal, Genetic Engineering, Humans, Mice, Transgenic, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fully human therapeutic monoclonal antibodies.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks